The effect of lipocisplatin on cisplatin efficacy and nephrotoxicity in malignant breast cancer treatment

Biomaterials

Volumn 35, Issue 24, 2014, Pages 6462-6472

  Li, Qun ^a   Tian, Yuantong ^b   Li, Dandi ^c   Sun, Jianfeng ^d   Shi, Donglei ^e   Fang, Lin ^f   Gao, Yong ^a   Liu, Haiyan ^d  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b GANNAN MEDICAL UNIVERSITY   (China)

^c CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^d JILIN UNIVERSITY   (China)

^e THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^f Changchun Medical College   (China)

Author keywords

Breast cancer; Cisplatin; Liposome; Nanoparticles; Nephrotoxicity

Indexed keywords

CARDIOVASCULAR SYSTEM; CELL CULTURE; DISEASES; LIPOSOMES; NANOPARTICLES; TUMORS;

BLOOD CIRCULATION; BREAST CANCER; BREAST CANCER CELLS; BREAST CANCER TREATMENT; CIS-PLATIN; HUMAN BREAST CANCER; NEPHROTOXICITY; TUMOR INHIBITION;

PLATINUM COMPOUNDS;

1-PALMITOYL-2-GLUTAROYL-SN-GLYCERO-3-PHOSPHORYLCHOLINE; CISPLATIN; DNA ADDUCT; ETHER PHOSPHOLIPID; LIPID;

ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CELL DEATH; CHEMISTRY; DNA ADDUCT; DOSE RESPONSE; DRUG EFFECTS; ENDOCYTOSIS; FEMALE; HUMAN; KIDNEY; MAMMARY NEOPLASMS, ANIMAL; MAXIMUM TOLERATED DOSE; METABOLISM; PATHOLOGY; SYNTHESIS; TISSUE DISTRIBUTION; TOXICITY; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL DEATH; CELL LINE, TUMOR; CISPLATIN; DNA ADDUCTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCYTOSIS; FEMALE; HUMANS; KIDNEY; LIPIDS; MAMMARY NEOPLASMS, ANIMAL; MAXIMUM TOLERATED DOSE; MICE, INBRED BALB C; PHOSPHOLIPID ETHERS; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 84901418982     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.04.023     Document Type: Article

References (27)

1. Wong E., Giandomenico C.M. Current status of platinum-based antitumor drugs. Chem Rev 1999, 99:2451-2466.
2. Abu-Surrah A.S., Kettunen M. Platinum group antitumor chemistry: design and development of new anticancer drugs complementary to cisplatin. Curr Med Chem 2006, 13:1337-1357.
3. Jamieson E.R., Lippard S.J. Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 1999, 99:2467-2498.
4. Wheate N.J., Walker S., Craig G.E., Oun R. The status of platinum anticancer drugs in the clinic and in clinical trials. Dalt T 2010, 39:8113-8127.
5. Miller R.P., Tadagavadi R.K., Ramesh G., Reeves W.B. Mechanisms of cisplatin nephrotoxicity. Toxins (Basel) 2010, 2:2490-2518.
6. Chirino Y.I., Pedraza-Chaverri J. Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol 2009, 61:223-242.
7. Sooriyaarachchi M., Narendran A., Gailer J. Comparative hydrolysis and plasma protein binding of cis-platin and carboplatin in human plasma invitro. Metallomics 2011, 3:49-55.
8. Kuang Y., Liu J., Liu Z., Zhuo R. Cholesterol-based anionic long-circulating cisplatin liposomes with reduced renal toxicity. Biomaterials 2012, 33:1596-1606.
9. Barui S., Saha S., Mondal G., Haseena S., Chaudhuri A. Simultaneous delivery of doxorubicin and curcumin encapsulated in liposomes of pegylated RGDK-lipopeptide to tumor vasculature. Biomaterials 2014, 35:1643-1656.
10. Zeng X., Morgenstern R., Nyström A.M. Nanoparticle-directed sub-cellular localization of doxorubicin and the sensitization breast cancer cells by circumventing GST-Mediated drug resistance. Biomaterials 2014, 35:1227-1239.
11. Immordino M.L., Dosio F., Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomed 2006, 1:297-315.
12. Kaasgaard T., Andresen T.L. Liposomal cancer therapy: exploiting tumor characteristics. Expert Opin Drug Del 2010, 7:225-243.
13. Gabizon A.A. Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. Clin Cancer Res 2001, 7:223-225.
14. Raj T.A., Smith A.M., Moore A.S. Vincristine sulfate liposomal injection for acute lymphoblastic leukemia. Int J Nanomed 2013, 8:4361-4369.
15. Flaten G.E., Chang T.T., Phillips W.T., Brandl M., Bao A., Goins B. Liposomal formulations of poorly soluble camptothecin: drug retention and biodistribution. JLiposome Res 2013, 23:70-81.
16. Seetharamu N., Kim E., Hochster H., Martin F., Muggia F. Phase II study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancer. Anticancer Res 2010, 30:541-545.
17. Boulikas T. Clinical overview on lipoplatin: a successful liposomal formulation of cisplatin. Expert Opin Investig Drugs 2009, 18:1197-1218.
18. Sengupta P., Basu S., Soni S., Pandey A., Roy B., Oh M.S., et al. Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity. Proc Natl Acad Sci USA 2012, 109:11294-11299.
19. Dourado F., Carreira H., Lunet N. Mammography use for breast cancer screening in Portugal: results from the 2005/2006 Nation Health Survey. Eur J Public Health 2013, 23:386-392.
20. Tao K., Fang M., Alroy J., Sahagian G.G. Imagable 4T1 model for the study of late stage breast cancer. BMC Cancer 2008, 8:228.
21. Rice J.R., Gerberich J.L., Nowotnik D.P., Howell S.B. Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system. Clin Cancer Res 2006, 12:2248-2254.
22. Li S.D., Howell S.B. CD44-targeted microparticles for delivery of cisplatin to peritoneal metastases. Mol Pharmacol 2010, 7:280-290.
23. Zhang X., Lin Y., Gillies R.J. Tumor pH and its measurement. JNucl Med 2010, 51:1167-1170.
24. Alexander-Bryant A.A., Vanden Berg-Foels W.S., Wen X. Bioengineering strategies for designing targeted cancer therapies. Adv Cancer Res 2013, 118:1-59.
25. Kiriyama A., Iga K., Shibata N. Availability of polymeric nanoparticles for specific enhanced and targeted drug delivery. Ther Deliv 2013, 4:1261-1278.
26. Kang J., Heart E., Sung C.K. Effects of cellular ATP depletion on glucose transport and insulin signaling in 3T3-L1 adipocytes. Am J Physiol-Endoc M 2001, 280:428-435.
27. Wong D., Colburn W.A., Gibaldi M. Fitting concentration-time data to bioexponential equations. JPharmacokinet Biopharm 1979, 7:97-100.